Abstract
To extend our knowledge of the pharmacological profile of human α4β2 neuronal nicotinic receptors, we investigated the action of hexamethonium on the major brain human nicotinic acetylcholine receptor (nAChR) stably expressed in human embryonic kidney 293 cells. This compound displays all of the characteristics of an open-channel blocker at the human α4β2 nAChR: a voltage-dependent inhibition (more pronounced at hyperpolarized potentials), absence of competition, and use dependence. Moreover, we observed that classicN-methyl-d-aspartate open-channel blockers amantadine, 3,5-dimethyl-1-adamantanamine (memantine), and dizocilpine [(+)-MK-801] and the calcium channel antagonist 8-(diethylamino)octyl-3,4,5-trimethoxybenzoate are powerful inhibitors of the human α4β2 nAChR. Dose-inhibition curves yield, at −100 mV, IC50 values in the micromolar range for all of compounds and Hill coefficients below unity. Whole-cell current-voltage relationships display a strong rectification profile at hyperpolarized potentials, and current blockades are fitted adequately by a mathematical model that describes the mechanism of an ion channel block. We conclude that these molecules are powerful human α4β2 open-channel blockers ranking in the following order of potency: amantadine > memantine = hexamethonium > 8-(diethylamino)octyl-3,4,5-trimethoxybenzoate ∼ (+)-MK-801.
Footnotes
- Received July 2, 1997.
- Accepted November 21, 1997.
-
Send reprint requests to: Dr. Daniel Bertrand, Dept. of Physiology, CMU, 1, rue M. Servet, CH−1211 Geneva 4, Switzerland. E-mail: bertrand{at}ibm.unige.ch
-
This work was supported by Swiss National Foundation Grant 31–37191.93 and by a grant from the Office Fédéral de l’Education et des Sciences (D.B.).
-
This work was presented in part at the 27th Annual Meeting of the Society for Neuroscience; 1997 Oct 25–30; New Orleans, LA.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
